Kohmann Bosshard Financial Services LLC Buys New Stake in Laboratory Co. of America Holdings (NYSE:LH)

Kohmann Bosshard Financial Services LLC bought a new stake in Laboratory Co. of America Holdings (NYSE:LH) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 240 shares of the medical research company’s stock, valued at approximately $55,000.

Several other large investors have also recently bought and sold shares of the business. Smartleaf Asset Management LLC increased its holdings in Laboratory Co. of America by 57.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 427 shares of the medical research company’s stock valued at $98,000 after buying an additional 156 shares during the last quarter. Duncker Streett & Co. Inc. increased its holdings in Laboratory Co. of America by 3.8% in the fourth quarter. Duncker Streett & Co. Inc. now owns 2,645 shares of the medical research company’s stock valued at $607,000 after buying an additional 98 shares during the last quarter. US Bancorp DE grew its holdings in shares of Laboratory Co. of America by 0.5% during the fourth quarter. US Bancorp DE now owns 22,421 shares of the medical research company’s stock worth $5,142,000 after purchasing an additional 118 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of Laboratory Co. of America by 62.8% during the fourth quarter. Fisher Asset Management LLC now owns 2,033 shares of the medical research company’s stock worth $466,000 after purchasing an additional 784 shares during the last quarter. Finally, Hahn Capital Management LLC grew its holdings in shares of Laboratory Co. of America by 47.6% during the fourth quarter. Hahn Capital Management LLC now owns 38,720 shares of the medical research company’s stock worth $8,879,000 after purchasing an additional 12,495 shares during the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Insider Activity at Laboratory Co. of America

In other news, CMO Amy B. Summy sold 226 shares of Laboratory Co. of America stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $250.40, for a total transaction of $56,590.40. Following the completion of the sale, the chief marketing officer now directly owns 4,544 shares in the company, valued at approximately $1,137,817.60. This trade represents a 4.74 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 1,314 shares of Laboratory Co. of America stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $251.30, for a total transaction of $330,208.20. Following the sale, the executive vice president now owns 2,171 shares of the company’s stock, valued at approximately $545,572.30. The trade was a 37.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,661 shares of company stock worth $2,119,118 over the last 90 days. Company insiders own 0.85% of the company’s stock.

Laboratory Co. of America Price Performance

Shares of NYSE:LH opened at $254.01 on Tuesday. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67. The company has a market cap of $21.26 billion, a P/E ratio of 28.80, a PEG ratio of 1.71 and a beta of 1.07. Laboratory Co. of America Holdings has a 52 week low of $191.97 and a 52 week high of $258.59. The company has a 50-day moving average price of $241.72 and a 200 day moving average price of $232.98.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. Research analysts predict that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current year.

Laboratory Co. of America Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be given a $0.72 dividend. The ex-dividend date is Thursday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.13%. Laboratory Co. of America’s payout ratio is currently 32.65%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Morgan Stanley raised their price objective on Laboratory Co. of America from $260.00 to $270.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Piper Sandler raised their price objective on Laboratory Co. of America from $240.00 to $260.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. StockNews.com raised Laboratory Co. of America from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Jefferies Financial Group raised their price objective on Laboratory Co. of America from $275.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Finally, UBS Group dropped their price objective on Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $265.75.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.